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Figure 1. Isolation of EMSY and Interaction Studies
(A) The complete exonic structure of the BRCA2 gene, expanded to show the previously described transcriptionally active region, and
then expanded again to show the results of alanine mutagenesis mapping of the BRCA2-EMSY interaction. The yeast two-hybrid bait
pBTM116.BRCA2.18–60 was sequentially mutated to establish which residues were important for endogenous transactivation activity in yeast,
and which could affect the interaction with EMSY in the yeast two-hybrid experiment. Yellow  mutations which reduce endogenous
transactivation capability but do not affect EMSY binding. Pink  mutations which both reduce transactivation and abolish EMSY binding.
(B) Evidence for the interaction between EMSY and BRCA2. EMSY associates with BRCA2 in GST pull-down. EMSY 1–478 was cloned in the
PING14 vector and used to in vitro translate (IVT) 35S-methionine-labeledrecombinant protein. Incubation of the radiolabeled EMSY (1–478)
resulted in binding to the fusion protein GST-BRCA2 (1–197), but not to the GST control.
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Soon after the cloning of BRCA1 and BRCA2, tran- each of these mutants was tested in the yeast two-
hybrid assay for interaction with EMSY. These experi-scriptional activation domains were described in both
ments showed that a short patch of 12 amino acids atproteins. One such domain is present in the highly con-
the BRCA2 N terminus is required for transcriptionalserved exon 3 of BRCA2 (Figure 1A) (Milner et al., 1997).
activation. The EMSY-BRCA2 interaction is affected byThe importance of this domain in the tumor suppressor
mutation of six of these residues.function of BRCA2 is suggested by the report of a breast
To confirm the interaction between EMSY and BRCA2,and ovarian cancer family whose germline mutation was
we used a bacterially expressed recombinant glutathi-shown to be an exact in-frame deletion of BRCA2 exon
one-S-transferase (GST) BRCA2 (1–197) fusion protein3 alone (Nordling et al., 1998), although such a deletion
to pull down the radiolabeled in vitro translated N-ter-might also have general effects on protein structure and
minal region of EMSY (1–478) (Figure 1B). The interactionfunction. The physiological role for a BRCA2 transactiva-
was also tested with transfection of the respective epi-tion domain remains uncertain. However, it has recently
tope-tagged mammalian expression constructs into 293Tbeen shown that BRCA2 can stimulate transcription of
cells, followed by coprecipitation and Western blottingandrogen receptor-regulated genes in cooperation with
of whole cell extract. EMSY (1–478) interacted specifi-histone acetytransferases (Shin and Verma, 2003).
cally with BRCA2 (18–60), corresponding to the exon 3Here we identify a protein, EMSY, which binds BRCA2
activation domain (Figure 1C). We then generated twoand like BRCA2 has functions associated with DNA re-
rabbit polyclonal anti-EMSY antibodies to short frag-pair and transcriptional regulation. EMSY has the ability
ments of recombinant bacterially expressed humanto contact chromatin-regulating proteins that contain
GST-EMSY proteins corresponding to EMSY aminothe newly defined Royal Family domain. Clinical studies
acids 130–180 (Abcam ab123) and EMSY amino acidsshow that the EMSY gene is frequently amplified in spo-
178–226 (ab2). Both antibodies strongly detected a sin-radic cases of breast and ovarian cancer.
gle band on Western blot of whole cell U2OS extract
running slightly slower than the predicted 160 kDa. Frac-
Results tionation experiments show that EMSY is exclusively
nuclear (data not shown). With these characterized
Isolation of EMSY EMSY antibodies, we used coimmunoprecipitation to
We performed yeast two-hybrid screens with small over- show that native BRCA2 and EMSY proteins associate
lapping sequences from the BRCA2 N terminus (Figure in vivo in untransfected cells (Figure 1D).
1A). A screen with the region of BRCA2 spanning amino Since we had shown that EMSY binds to residues that
acids 1–46 identified 10 specifically interacting clones, are involved in transcriptional activation, we asked if the
while an overlapping region (amino acids 18–60) yielded binding of EMSY might affect this activity. Figures 1E
6 clones. All sixteen interactors proved to be fragments and 1F show that the expression of EMSY 1–478 sup-
of the same cDNA, encoding a protein which we have presses the activity of GAL4-BRCA2 18–60, but does
called EMSY (since the word “SISTER” appears in the not affect the activity of a control fusion GAL4-E2F. The
first line of the protein sequence, we named this protein EMSY 1–478 region possesses independent repressive
after the first author’s sister, who is a breast cancer functions, since a GAL4-EMSY 1–478 fusion is able to
nurse). These results indicate that a region at the amino silence transcription of a high basal level promoter (Fig-
terminus of EMSY (corresponding to amino acids 1–80 ure 1G).
of the predicted EMSY protein) binds within residues Collectively, these results demonstrate that EMSY is
18–46 of BRCA2 exon 3. a repressor protein which has the capacity to bind a
We examined the EMSY binding site within the BRCA2 small epitope within the BRCA2 exon 3-encoded tran-
exon 3 activation domain with an alanine scanning muta- scriptional activation domain and specifically silence
genesis approach (Figure 1A). The interaction site was this activity.
narrowed down to the BRCA2 amino acid region 23–46
with a deletion series (not shown). Each amino acid EMSY Relocalization to Sites of DNA Damage
residue within this critical region of BRCA2 was then Immunofluorescence studies with the anti-EMSY anti-
body (Abcam ab123) showed that EMSY is nuclear, withmutated to alanine with site-directed mutagenesis, and
(C) EMSY (1–478) coimmunoprecipitates with BRCA2 (18–60) from transfected cellextracts. Epitope-tagged fragments of EMSY (pcDNA.EMSY1–
478.myc) and BRCA2 (pcDNA.HA.BRCA2.18–60) were transfected into 293T cells, immunoprecipitated with an anti-HA (haemagglutin) antibody
(Boehringer-Mannheim), and Western blotted with an anti-myc antibody (Roche).
(D) Endogenous coimmunoprecipitation of EMSY and BRCA2 from unmanipulated asynchronously dividing HeLa cells. Immunoprecipitation
with an unrelated antibody (anti-green fluorescent protein, Abcam, Cambridge, UK), preimmune serum (from a different rabbit), or anti-BRCA2
antibody (Ab-2, Oncogene Research Products, San Diego CA) was followed by Western blotting with the affinity-purified anti-EMSY antibody
(Abcam ab123). Neither of the unrelated antibodies could coprecipitate EMSY, whereas an EMSY signal was detected in the immunoprecipitate
obtained with the anti-BRCA2 antibody. The anti-EMSY antibody was also used to immunoprecipitate endogenous EMSY protein.
(E) EMSY N terminus specifically represses BRCA2 transcriptional activity. Cotransfection of increasing amounts of pcDNA.EMSY (1–478)
repressed the ability of the pCMV.GAL4. BRCA2 18–60 region to activate a reporter construct in a CAT assay, and this effect was shown to
be specific in (F), since no effect was seen on the E2F activation domain.
(G) EMSY was also shown to have endogenous repressive functions. Amino acids 1–478 of EMSY were cloned as a fusion protein to GAL4
to allow recruitment to a GAL4 coupled high basal TK promoter driving expression of the CAT gene. Transient transfection of increasing
amounts (0.5 and 5 g) of the pcDNA3.GAL4-EMSY1–478 construct caused increasing transcriptional repression. The activity of the reporter
in the presence of the empty pcDNA-GAL4 vector was normalized to 100.
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Figure 2. EMSY Relocalizes in Response to DNA Damage
(A) EMSY responds to DNA damage. EMSY antibody immunofluorescence staining of immortalized mouse wild-type embryonic fibroblasts
before and after treatment with ionizing radiation (10 Gray at 1.8 Gy/minute, 250 kVp). EMSY assembles into nuclear speckles over several
hours (see graph in [B] for time course). Costaining with a monoclonal mouse antibody to -H2AX (Roche) reveals that EMSY relocalizes to
DNA damage sites.
a granular appearance (Figure 2A). We asked whether the Royal Family of protein domains. Royal Family mem-
bers include Chromo, PWWP, MBT, Tudor, and AgenetEMSY can relocalize to sites of DNA repair after DNA
damage, as is the case with BRCA2. Figure 2 shows that (Figure 3C). These domains are similar in both primary
treatment with ionizing radiation causes a substantial sequence (Maurer-Stroh et al., 2003) and tertiary struc-
increase in the number of cells with EMSY-containing ture. Representatives of Tudor, PWWP, Chromo, and
nuclear speckles. The time course of DNA damage- MBT have recently been solved at the structural level.
induced speckling in the wild-type cells is shown (Figure Our examination of these structures shows that they
2B). To establish whether EMSY relocalizes to DNA re- exhibit a common fold. Within this common fold, there
pair sites, we performed coimmunofluorescence experi- is conservation of aromatic residues found within the
ments with an anti-phospho-histone 2AX (-H2AX) anti- HP1 chromodomain, which are known to recognize
body. H2AX is phosphorylated rapidly in response to methylated lysines within histones (Nielsen et al., 2002;
DNA damage, forming -H2AX speckles that mark the Jacobs and Khorasanizadeh, 2002). These findings raise
site of DNA repair (Paull et al., 2000). EMSY colocalizes the possibility that some members of the Tudor, PWWP,
almost completely with -H2AX foci after radiation (Fig- and MBT family may also be recognizing modified his-
ure 2A), suggesting that EMSY has some role in DNA tones. This would be compatible with the fact that these
repair. These immunofluorescence experiments were domains are often found in chromatin regulating pro-
performed in a spontaneously immortalized wild-type teins.
murine embryonic fibroblast cell line derived in the Ven-
kitaraman laboratory. To date, demonstration of dam-
An HP1 and BS69 Binding Platform within EMSYage-inducible EMSY speckling in human cell lines has
We performed yeast two-hybrid screens with the firstbeen unsuccessful.
140 amino acids of EMSY (which includes the ENT do-
main) in an attempt to gain some insight into the functionThe EMSY ENT Domain and Plant Agenet Domains
of this protein. We noticed that over 80% of the 112The complete EMSY cDNA sequence was cloned. The
interacting clones encoded proteins that containedopen reading frame encodes a predicted protein of 1322
Royal Family domains. These include HP1 (which has aamino acids. The sequence is entirely novel. There are
chromodomain), BS69 (PWWP domain), and a novelno other EMSY-like proteins in the human genome, and
MBT domain-containing protein. This suggests thata single EMSY gene can be found in frogs and fish
EMSY may coordinate the binding of proteins containing(Figure 3A). However, we identified an 80 amino acid
the Royal Family domain. To test this, we chose twoevolutionarily conserved domain at the amino terminus
interactors, HP1 and BS69, for further study.of EMSY, which we have called the EMSY N-Terminal
All three isoforms of HP1 (, , ) were detected indomain (ENT domain; Pfam number PF03735) (Figure 3A).
the preliminary yeast two-hybrid screens. The interac-In Arabidopsis, there are 9 different proteins which pos-
tion was also seen between recombinant bacterial ex-sess an ENT domain. Examination of these genes shows
pressed EMSY and each of the HP1 isoforms in a GSTthat they all contain a new Tudor-like domain, which we
pulldown (Figure 4A). However, in an endogenous co-call the Agenet domain (Pfam number PF05641)
immunoprecipitation, we were only able to confirm that
EMSY and HP1 interact in vivo (Figure 4B), whereasEMSY and the Royal Family Connection
we could not demonstrate an interaction between EMSYAs we have recently reported (Maurer-Stroh et al., 2003),
the Agenet domain forms part of a superfamily we term and HP1 or HP1 (data not shown).
EMSY in Sporadic Breast and Ovarian Cancer
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Figure 3. EMSY Bioinformatics
(A) Multiple sequence alignment of ENT domains presented using CHROMA and a 75% consensus. Species abbreviations (with accession
numbers in brackets): mosquito, Aedes aegypti (agCP8691); plant, Arabidopsis thaliana (accession numbers given in figure); human, Homo
sapiens (CAD22881); Drosophila, Drosophila melanogaster (CG15356); zebrafish, Danio rerio (EST 14163341); rootknot worm, Meloidogyne
javanica (EST 9829797); strongyloides, Strongyloides ratti (EST 14288209); and frog, Silurana tropicalis (EST 17663399).
(B) Schematic stick figure representation of the eight Arabidopsis ENT-Agenet proteins. The ENT domain is shown in pink, the Agenet domain
in green.
(C) Diagram of the Royal Family of domains, illustrating the possible evolutionary divergence from a single ancestral domain. Within the Royal
Family, there are five domains that contain sequence similarity. These are PWWP (Stec et al., 2000), MBT (Bornemann et al., 1998), Tudor
(Yang et al., 2003), Agenet (Maurer-Stroh et al., 2003), and the chromodomain (Jones et al., 2000). Each Royal Family member has been
implicated in chromatin remodeling functions. The PWWP domain was named after its central core “Pro-Trp-Trp-Pro,” and is usually found
with other chromatin-associated domains such as the SET, bromo-, and PHD domains; they may be involved in the heterochromatin localization
of the DNA methyltransferase, Dnmt3a (Bachman et al., 2001) The Tudor domain was first identified in the Drosophila Tudor protein (the tudor
phenotype includes male sterility, which is often thought to be characteristic of the Tudor kings of England, hence the name), and is also
found in a lysine-specific histone methyltransferase that contributes to HP1-mediated silencing (Schultz et al., 2002). The chromodomain was
first identified as a homology between heterochromatin protein 1 (HP1) and polycomb protein (Pc), and is crucial for targeting to methylated
histone tails (Bannister et al., 2001; Lachner et al., 2001); the MBT (malignant brain tumor) domain was identified during a screen for tumor
suppressor genes in Drosophila and is confined to members of the polycomb group of proteins which are involved in the maintenance of
heterochromatic states (Bornemann et al., 1998).
Using deletions of both HP1 and EMSY, we found that tagenesis of two residues within this region, V100A and
L102A, abolished the binding of GST-EMSY to his-HP1,the HP1 chromoshadow domain interacts with EMSY
(Figure 4C). Deletion mapping narrowed down the inter- confirming that this region is central to the EMSY-HP1
interaction (Figures 4E and 4F).action site within EMSY to a region between amino acids
80 and 140 (data not shown), and examination of this To analyze the EMSY-BS69 interaction in vivo, we
had to transfect epitope-tagged BS69 into cells, sinceregion revealed a candidate HP1 binding consensus site
adjacent to the ENT domain (Figure 4D). Combined mu- antibodies against BS69 are not available. Figure 5A
Cell
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Figure 4. Evidence for HP1 Binding adjacent to the EMSY ENT Domain
(A) GST pull-downs of bacterially expressed recombinant His-EMSY (1–140) by each of the three isoforms of GST-HP1.
(B) Coimmunoprecipitation of EMSY and HP1. HP1 (molecular weight 28 kDa) is predicted to run just below the light chain from the
immunoprecipitating rabbit antibody (31 kDa), and a band doublet corresponding to HP1 and the light chain can be seen at this position
after IP with the EMSY antibody in a 10% SDS-PAGE gel, but not with the preimmune sera (where a single band corresponding to the light
chain can be seen). This experiment was repeated with a 17.5% gel (lower panel) to achieve better separation of the immunoglobulin light
chain and HP1; neither the preimmune sera or an unrelated antibody (anti-GFP) was able to immunopurify HP1, but the anti-EMSY antibody
does, confirming the interaction in vivo. The HP1 antibody was purchased from Upstate.
(C) GST fusion protein pull-down of his-tagged HP1 deletions reveals that the EMSY interaction is mediated through the HP1 chromoshadow
domain. An anti-his tag antibody was used to detect the pull-down proteins (Quiagen). CSD, chromoshadow domain; CD, chromodomain;
FL, full-length.
(D) Deletion mapping of the EMSY amino terminus narrowed down the interaction site to a region between amino acids 80 and 140 (data not
shown). Sequence comparison of HP1 binding sites suggests a possible HP1 binding site in EMSY. Pep  peptides isolated from a random
peptide display phage library; hCAF1  human chromatin assembly factor 1; hTIF1  human transcription intermediate factor 1 (Smothers
and Henikoff, 2000).
(E) Alanine mutagenesis of the GST-EMSY fusion protein demonstrates that EMSY residues 100 and 102 are indeed critical for the HP1 inter-
action.
(F) Summary diagram illustrating a binding platform for two Royal Family domain-containing proteins, HP1 and BS69, lying adjacent to the
ENT domain in EMSY.
EMSY in Sporadic Breast and Ovarian Cancer
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Figure 5. Evidence for BS69 Binding adjacent to the EMSY ENT Domain
(A) Coimmunoprecipitation of endogenous EMSY and HA-BS69 from HA-BS69 transfected HeLa cells, using the previously characterized anti-
EMSY antibody (Abcam ab123) for IP and a mouse monoclonal anti-HA antibody (Boehringer-Mannheim) for Western detection.
(B) Pull-down of HA-BS69 from transfected 293T whole cell extracts with EMSY (1–140)-GST fusion protein.
(C) Evidence for a BS69 core binding motif in EMSY; the sequence is compared to core motifs in known BS69 interactors (E1A  adenoviral
E1A oncoprotein; EBNA  Epstein Barr nuclear antigen; CR7 and CR8 refer to conserved regions of the EBNA protein; MGA  myc related
cellular transcription factor) (Ansieau and Leutz, 2002).
(D) Mutation analysis confirms that the PxLxP motif at position 103–108 of EMSY is critical for the BS69-EMSY interaction.
(E) Deletion analysis shows that the EMSY interaction is mediated through the MYND domain of BS69, and that mutation of the BS69 core
binding site abolishes the BS69 interaction.
shows that the immunoprecipitation of endogenous pletely abolishes the binding of EMSY to HA-tagged full
length BS69 (Figure 5D), and a deletion analysis revealedEMSY coprecipitates an HA-tagged BS69 protein. The
N terminus of EMSY (residues 1–140) is sufficient to bind that the MYND domain of BS69 is sufficient for this
interaction (Figure 5E).BS69, since a GST-EMSY (1–140) fusion protein can
purify transiently transfected HA-tagged BS69 (Fig- Together these results indicate that the HP1 chro-
moshadow domain interacts with a VPL motif in EMSY,ure 5B).
A binding motif for BS69 (PXLXP) has been described whereas the MYND domain of BS69 interacts with a
PXLXP motif in EMSY. The binding sites for HP1 andfor a number of BS69 partners (Figure 5C). This motif
was found at amino acids 104–108 of EMSY, which falls BS69 with EMSY abut each other, and are found directly
adjacent to the ENT domain of EMSY. This demonstrateswithin the EMSY binding domain for BS69 (EMSY1–140)
(Figure 4F). Mutation of the PXLXP motif to PXAXP com- that EMSY has the capacity to contact directly at least
Cell
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two proteins which contain a Royal Family domain. pendently overexpressed in breast cancer. Furthermore,
the very low levels of GARP expression in the five cellSince this domain is found in proteins with a chromatin
connection, we assume that EMSY functions, at least lines with EMSY/GARP genomic amplification suggest
that EMSY, not GARP, is the critical gene in this am-partly, in the regulation of chromatin.
plicon.
Next, a previously described collection of sporadicEMSY’s Status in Breast Cancers
primary breast cancers was examined with SouthernThe EMSY gene locus maps to chromosome 11q13.4-5
blotting (Courjal et al., 1997). We found high-level EMSYby FISH and radiation hybrid mapping. This gene-dense
amplification in 65 (7.4%) of 875 of these sporadic breastregion has been extensively implicated as a site of ampli-
cancers. Again, in order to establish whether EMSY am-fication in sporadic breast cancer (Bekri et al., 1997;
plification could occur independently of other genes inOrmandy et al., 2003). A single gene cannot be responsi-
this region, probes to the GARP, Cyclin D1, and EMS1ble for all the amplifications at 11q13, because at least
genes were also used in Southern blotting. EMSY ampli-four distinct cores of amplification have been recog-
fication occurs independently of Cyclin D1 in 40% ofnized (Figure 6; Bekri et al., 1997; Ormandy et al., 2003).
cases. These results show that the EMSY/GARP geneRecently, the physical map of this region has been com-
region is amplified in breast cancer, and that it is notpleted (Chromosome 11, build 33, www.ncbi.nlm.nih.
simply being amplified as a passenger to Cyclin D1, agov/genome/guide/human), and it reveals that three
well-characterized breast cancer oncogene which liescores are clustered within a 1.4 Mb interval. Cyclin D1
6 Mb centromeric to EMSY.and EMS1 are strong candidates for driving amplifica-
tion at two cores within this cluster, whereas the candi-
date gene for the third (D11S97) is unknown. EMSY Amplification Is Associated with a Poor
Prognosis in Human Breast CancerA further core is defined by the GARP gene (Bekri et
al., 1997). The GARP amplicon lies 6 Mb telomeric to We then asked whether EMSY amplification is associ-
ated with clinical outcome by using FISH in tissue mi-the other cores, a physical separation which may explain
why this locus has the highest independent amplification croarrays (Kononen et al., 1998) of primary sporadic
tumors sent to Vancouver Hospital during 1976 to 1990.frequency of all the amplicons on 11q13 (Ormandy et
al., 2003). Strikingly, EMSY lies immediately adjacent to Clinical data and outcome, including all breast cancer
recurrences and deaths, were available for all patients.the GARP gene, within 0.1 Mb. Therefore, it must also be
contained in this well-described breast cancer amplicon Amplification ratios for EMSY and Cyclin D1 were ob-
tained by normalizing gene copy number against centro-(Figure 6A).
To investigate whether EMSY is amplified in breast mere 11 copy number. FISH for EMSY gene copy number
was successful in 551 of 928 cases. There was no differ-cancer, we used FISH (fluorescence in situ hybridization)
to examine metaphase spreads from 28 breast cancer ence in survival between cases with and without EMSY
data (p  0.79).cell lines. We also did some intraoperative touch prepa-
rations from five newly diagnosed sporadic breast pri- This more sensitive FISH-based analysis showed
EMSY amplification (copy number ratio greater than 1.5)mary cancers, and found one with gross EMSY amplifi-
cation (Figure 6B). In the breast cancer cell lines, we in 70 of the 551 breast cancers (13%). In 49 of these
there were more than 5 copies of EMSY per cell. Cyclinfound that five of the 28 (18%) had EMSY amplification
(Table 1, middle column). In one of these cell lines, mas- D1 amplification was seen in 78 cancers (14%), and
was present in only a subset of cancers with EMSYsive amplification of EMSY was independent of Cyclin
D1 (Figure 6B, left panel). amplification (42/70 [60%]), which again suggests that
both genes are independent oncogenic targets; this pro-Next, we asked whether this genomic amplification of
the EMSY gene results in increased expression of EMSY. portion of Cyclin D1-independent EMSY amplification
agrees exactly with the data obtained by Southern blot-Quantitative RT-PCR confirmed that cell lines with
EMSY genomic amplification also had the highest levels ting on a different set of sporadic breast cancers de-
scribed above.of EMSY expression (Table 1, right column).
In order to confirm that the EMSY amplicon could be Examination of records from the cases described
above indicates that the median disease-specific sur-independently amplified, we performed array compara-
tive genomic hybridization (CGH) on key genes across vival was 6.4 years for node-negative cases with EMSY
amplification (copy number ratio 1.5), versus 14 yearsthe locus: CCND1, EMS1, GARP, and PAK1, and FISH for
EMSY (Supplemental Table S1 at http://www.cell.com/ for node-negative cases without EMSY amplification.
Overall, patients with EMSY amplification had a worsecgi/content/full/115/5/523/DC1; see Figure 6A for a de-
scription of gene order relative to amplicon cores). We disease-specific survival compared to patients without
EMSY amplification (p 0.002) (Figure 7A). Remarkably,found that in the SUM52 cell line, the amplification inter-
val involved only EMSY and GARP, and not genes from this effect was confined to node-negative breast cancer
patients (p  0.0004) compared to node-positive casesthe more centromeric amplification cores, or PAK1
which lies immediately telomeric. This confirms previous (p  0.14) (Figures 7B and 7C). A similar effect is seen
on overall survival (data not shown). The effect of EMSYreports of independent amplification at this locus (Bekri
et al., 1997). amplification on survival in patients with node-negative
disease remained significant in a multivariate analysisWhen the expression of EMSY and GARP was com-
pared in the SUM52 cell line, EMSY was found to be presented below the graph in Figure 7B. We were also
able to show that the survival of patients with EMSYoverexpressed by 6-fold, whereas GARP was barely de-
tectable. These results confirm that EMSY can be inde- amplification was not affected by the presence of con-
EMSY in Sporadic Breast and Ovarian Cancer
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Figure 6. EMSY Amplification in Breast Cancer
(A) Chromosomal mapping of EMSY. The recently available physical map of the chromosome 11q13.4-5 breast cancer amplified region is
displayed next to the cytogenetic map of chromosome 11. The gene order within this region is also listed. Three of the four known breast
amplicon cores (D11S97, CCND1/CyclinD1, and EMS1) are clustered within a 1.4 Mb interval, which contains only 20 genes. The fourth core
(GARP) lies 6 MB telomeric to this three-core cluster. Within the GARP core, EMSY can be seen lying immediately centromeric to GARP in
the gene order (and within 0.1 Mb on physical mapping). The genes discussed in the text are shown in larger type within the amplicon.
(B) Left panel shows high-level genomic amplification of EMSY by FISH in the SUM52 breast cancer line. The EMSY probe is labeled green,
and a large homogenously staining region (HSR) is seen together with EMSY genomic insertions in other chromosomal regions, a feature of
high-level genomic amplification. The simultaneous hybridization with the Cyclin D1 (red) shows that EMSY amplification is independent of
Cyclin D1 in this cell line. Right panel shows high level EMSY amplification in a primary breast cancer (touch prep of surgical specimen) with
EMSY (green) and centromere 11 probe (red).
current Cyclin D1 amplification (Figure 7B). We conclude carcinomas (62/360) and 0% of low-grade or borderline
ovarian cancers (0/110) (p 0.001). In contrast to breastthat EMSY amplification identifies a subset of breast
cancers associated with a poor prognosis. cancer, we found that Cyclin D1 amplification (11%) was
less common than EMSY amplification (17%), and EMSY
was less likely to be coamplified with Cyclin D1 (40%EMSY’s Status in Ovarian Cancer
EMSY was assessed in ovarian cancers with tissue of EMSY amplification cases had Cyclin D1 coamplifica-
tion). Thus, EMSY rather than Cyclin D1 appears to bearrays. Amplification was seen in 17% of high-grade
Cell
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Table 1. Genomic Amplification Is Accompanied by EMSY
Overexpression
Cell Line Copy Number Ratio Ranked Expression
SUM44 5 1
SUM52 5 2
MDA-MB-175 5 3/4 (tied)
SUM190 5
MATU 1.7 5
VP229 1.0 6
MDA-MB-453 1.4 7
OCUB-M 0.9 8
VP267 1.5 9
MDA-MB-361 0.9 10
MDA-MB-436 0.9 11
MDA-MB-468 1.5 12
Kpl-1 1.2 13/14 (tied)
SUM102 1.3
SKBR3 1.0 15
MT-3 1.0 16/17 (tied)
MDA-MB-231 1.2
ZR-75-1 0.6 18
MDA-MB-157 1.0 19
BT549 1.0 20
SUM185 1.5 21
MCF-7 1.5 22
CAL51 1.0 23
SUM149 1.1 24
MDA-MB-134 5 not performed
MDA-MB-435S 1.1 not performed
DU4475 1.0 not performed
MCF-7 1.5 not performed
The name of each of the 28 breast cancer cell lines analyzed in this
study is listed in the left hand column. EMSY genomic copy number
is recorded in the middle column. In the right hand column, EMSY
expression levels are ranked, with the highest expressing cells at
the top (real time PCR estimation of relative mRNA levels). EMSY
expression was assessed using ABI TAQMAN real-time PCR in a
subset of 24 of the cell lines in which EMSY genomic copy number
had been determined. Two independent probes for EMSY were
designed and gave similar results. The ranking shows that cell lines
previously found to have genomic amplification of EMSY by FISH
also ranked highest in EMSY mRNA levels. The expression study
was performed blind on numbered samples and EMSY expression
levels were ranked before the number codes were broken to identify
the cell lines.
a more frequent gene amplification event involving
11q13 in ovarian cancers.
EMSY’s Status in Non-Breast/-Ovarian Cancers
We also examined EMSY amplification in non-breast/
Figure 7. EMSY Amplification Is Associated with a Worse Outcome
-ovarian cancers using multitumor arrays. EMSY amplifi- in Breast Cancer
cation was seen in 1/5 hepatocellular carcinomas, 1/7 Kaplan-Meier curves comparing breast cancer mortality between
melanomas, and 1/57 endometrial carcinomas, but was women with EMSY normal and EMSY amplification breast cancer,
not identified in more than 200 other cancers from a showing correlation between EMSY amplification and breast cancer
mortality in all 551 cases (A), in node-negative cases (B) and inwide range of primary sites, including 21 sarcomas and
node-positive cases (C). The table below (B) summarizes the results34 colorectal carcinomas.
of a Cox proportional hazard regression multivariate analysis to
determine the effects of tumor size (2 cm versus 2 cm), EMSY
Discussion amplification (amplification ratio 1.5 versus amplification ration	
1.5), Cyclin D1 amplification (amplification ration 1.5 versus ampli-
fication ration 	 1.5), and estrogen receptor (ER) status (10%We have cloned EMSY, a human breast and ovarian
versus 	10% nuclear immunoreactivity) status on survival in nodecancer gene. The EMSY protein interacts precisely with
negative patients.a highly conserved transactivating region at the N termi-
nus of the breast cancer protein BRCA2, and has endog-
enous transcriptional repressor activity when recruited
to a high basal promoter. EMSY is exclusively nuclear
EMSY in Sporadic Breast and Ovarian Cancer
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and relocalizes after DNA damage to -H2AX speckles. EMSY may reflect a role in DNA repair just as much as
in transcriptional regulation.H2AX is essential for the efficient recognition and repair
of DNA double-strand breaks (DSBs), and becomes rap-
idly phosphorylated to -H2AX at the site of each na- EMSY’s Involvement in Breast and Ovarian Cancer
We find that EMSY amplification is almost never seenscent DSB, resulting in characteristic nuclear foci (Pilch
et al., 2003). BRCA2 is also known to relocalize to DSB in a wide range of non-breast/-ovarian cancers. Further-
more, in ovarian cancer, EMSY amplification is confinedrepair sites after DNA damage. These results suggest
that the functions of EMSY and BRCA2 (two breast can- to grade 2 or 3 subtypes, not grade 1 or borderline (low
malignant potential) tumors. This spectrum of pathologycer-specific genes) are connected.
for EMSY amplification exactly matches that seen in
familial ovarian cancer from BRCA2 mutation carriers
EMSY Organizes Chromatin Regulators (Boyd et al., 2000; Risch et al., 2001). These findings are
Containing the Royal Family Domain important because they show that an abnormality in a
Although EMSY is a large protein, its primary amino acid BRCA2 interacting protein might incriminate BRCA2 it-
sequence is uninformative except for a novel evolution- self in sporadic cancers. This is an important goal, be-
ary conserved domain we have called ENT. In plants, cause despite strenuous worldwide efforts since BRCA2
proteins containing the ENT domain invariably contain was cloned over 8 years ago, it has not yet been possible
an Agenet domain. This domain is likely to have a role to show how (or if) BRCA2 is involved in sporadic breast
in chromatin regulation. In contrast, EMSY does not cancers. BRCA2 is rarely (if ever) mutated in these can-
possess a Royal Family domain within its sequence but cers. The fact that EMSY amplification and BRCA2 dele-
does associate with proteins containing such domains. tion display the same pathology in sporadic and familial
This suggests that EMSY’s function may be connected cancers suggests that overexpression of EMSY and de-
to chromatin regulation. letion of BRCA2 have a similar effect on a given pathway.
We can only speculate as to which function of these
two proteins is impinging on the cancer-predisposingRole of EMSY in Transcription and DNA Repair
pathway. However, at one level of analysis presentedThe ability of EMSY to assemble chromatin-remodeling
here, regarding their transcriptional activation functions,proteins adds weight to the emerging role for both the
it is possible to imagine that deletion of the BRCA2BRCA proteins in chromatin remodeling. A large BRCA2
activation domain in exon 3 may have the same effectcomplex has recently been described which includes
as overexpressing EMSY, a repressor of this BRCA2proteins strongly reminiscent of the SWI/SNF group and
activity. Certainly the physical, functional, and clinicalwhich has the capacity to deacetylate histones (Hakimi
relationships between EMSY and BRCA2 presentedet al., 2002); it has also been shown that BRCA1-SWI/
here strongly suggest that the pathways they regulateSNF is the predominant BRCA1-containing complex in
are intimately linked.HeLa nuclear extract (Bochar et al., 2000) and that tar-
geting of BRCA1 to chromosomal regions in the mam-
Experimental Proceduresmalian genome results in large-scale chromatin decon-
densation (Ye et al., 2001). It is not yet clear exactly how Yeast Two-Hybrid Screen
chromatin-remodeling functions relate to the known The yeast plasmids pVP16 and pBTM116 and mouse embryo (day
10.5) cDNA library were a gift from Dr. Stanley Hollenberg (OregonDNA repair activity of the BRCA proteins, although two
Health Sciences University, Portland, OR), and the screens werescenarios have been envisaged: either they are required
performed with 50 mmol 3AT (3-amino-1,2,4-triazole) to suppressfor the activation of DNA damage response genes or
the endogenous activity of the cloned fragments from BRCA2for allowing the DNA repair machinery access to its
exon 3.
substrate. Repair genes such as GADD45 are known
to be major transcriptional targets for BRCA1, which In Vitro Pull-Downs and Alanine Scanning
The pGEX2TK and PET30 plasmids were used in standard protocolsprovides some support for the first scenario (Harkin et
for synthesis of bacterially expressed proteins, and the TNT T7al., 1999), while reports of rapid changes in chromatin
Coupled Reticulocyte Lysate System (Promega, WI) was used tostructure and accessibility after DNA damage provide
synthesize radiolabeled protein for pull-downs. Alanine mutationssome support for the second (Downs et al., 2000). An-
were introduced with the Quickchange method (Stratagene).
other possibility is that aberrant chromatin remodeling
might itself lead to genomic instability (Myung et al., Tissue Culture and Transactivation Assays
Cell lines were maintained in DMEM supplemented with 10% fetal2003).
calf serum and grown at 37
C in 5% CO2. The pCDNA3 GAL4 (1–147)We have suggested that the independent activation
vector was used for CAT assays; activity was normalized to 100%domain of BRCA2 within exon 3 might have some role
for the cells transfected with the control vectors; for transactivationin transcription (Milner et al., 1997). The identification of
assays, the reporter construct contained five tandem repeats of the
the repressor protein EMSY, which binds and silences Gal4 binding site upstream from the CAT gene; for repression
this domain, is consistent with such a function. However, assays, 0.5 microgram of high basal reporter pGal4-TK-CAT was
used.the distinction between transcription and repair at the
chromatin level now seems outmoded, as it has recently
Coimmmuoprecipitationsbecome evident that changes in chromatin occur after
Subconfluent cells were lysed in NETN buffer (20 mM Tris-Cl [pHDNA damage (Fyodorov and Kadonaga, 2001), and
8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) with protease inhibitors
these changes are often indistinguishable from the (Boehringer), and supernatant from the lysate was precleared with
changes that precede transcription. It is therefore possi- beads and immunoprecipitated overnight with antibody. The immu-
noprecipitate was collected on protein A/G sepharose beads,ble that the activation/repression function of BRCA2/
Cell
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